J Nucl Med. 2007; 48 (Supplement 2):57P
Neurosciences: Neurology
Amyloid Imaging in Dementia |
First results from human studies of a novel F-18 PET ligand for brain ß–amyloid imaging
Christopher Rowe1,
Steven Ng1,
Rachel Mulligan1,
Uwe Ackermann1,
William Browne1,
Graeme O'Keefe1,
Henri Tochon-Danguy1,
Gordon Chan1,
Hank Kung3,
Mei-Ping Kung3,
Daniel Skovronsky4,
Thomas Dyrks5,
Gerhard Holl5,
Sabine Krause5,
Matthias Friebe5,
Stefanie Lindemann5,
Wolf Sittner5,
Ludger Dinkelborg5,
Colin Masters2 and
Victor Villemagne1
1 Centre for PET, Austin Hospital, Melbourne, Victoria, Australia; ;
2 Pathology, University of Melbourne, Melbourne, Victoria, Australia; ;
3 Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; ;
4 Avid Radiopharmaceuticals Inc., Philadelphia, Pennsylvania; ;
5 Bayer Schering Pharma AG, Berlin, Germany; ;
6 The Mental Health Research Institute of Victoria, Melbourne, Victoria, Australia
188
Objectives: C-11 PIB PET has proven useful for the detection of beta-amyloid (Aß) in vivo in Alzheimer’s disease. However, the 20-minute half-life of C-11 restricts the use of PIB to centres with an on-site cyclotron. The aim of this study was to assess the lead compound from a novel series of F-18 labelled amyloid imaging ligands in AD patients and age-matched healthy controls (HC). Methods: Five mild AD subjects (MMSE 24±3, CDR 1) and 5 HC (MMSE >28) underwent PET imaging over 3 hours after injection of 300 MBq of the F-18 ligand. Distribution volume ratios (DVR) were calculated through graphical analysis using the cerebellum as input function. Results: All AD subjects showed neocortical binding, greatest in the precuneus/posterior cingulate and frontal cortex, followed by lateral temporal and parietal, with relative sparing of sensorimotor cortex. HC showed no binding in cortical or subcortical grey matter and their scans were clearly distinguishable from AD subjects. Cerebellar cortex showed no retention in either group. Significantly higher neocortical DVRs were observed in AD (1.84 ± 0.20) when compared with HC (1.3 ± 0.17, p = 0.009). Cortical uptake to cerebellar cortex ratio (SUVR) at 90-120 minutes post-injection gave similar results to DVR. Conclusions: Our results show that Aß burden can be quantified in AD with a novel F-18 labelled PET ligand. The pattern of binding closely matches that reported with 11C-PIB. This ligand may permit wide application of amyloid imaging by centralized production and distribution not possible with a C-11 labelled Aß ligand.
Research Support (if any): Neurosciences Victoria Ltd, Austin Hospital Medical Research Foundation, and the University of Melbourne
